| |
ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big NewsDec 4, 2023 |
|
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility. 
|
|
| By Nick Paul Taylor Roche is paying $2.7 billion upfront to enter the obesity market. The takeover will give Roche control of Carmot Therapeutics, a biotech with injectable dual GLP-1/GIP receptor agonists and an oral GLP-1 drug in clinical development. |
|
|
|
By Gabrielle Masson Seismic Therapeutic has secured a series B of significant magnitude, snagging $121 million and new investor Amgen Ventures in a round aimed at pushing two immunology programs into the clinic. |
By Max Bayer Merck KGaA’s year-long quest to become leaner and rely more on external innovation has led to a $70 million partnership with Chinese biotech Abbisko Therapeutics for rights to a late-stage joint tumor med called pimicotinib. |
Sponsored by Cell Signaling Technology CST fellow Amrik Singh outlines some of the key progress being made around CAR-T therapy and the impact that this highly specialized technique can have on cancer patients, even those who have been previously unresponsive to other forms of treatment. |
|
Regulatory guidance recommends examining carboxylesterase-mediated metabolism for drugs without significant CYP metabolism, so here’s what you need to know: Learn More >> .jpg)
|
|
By Nick Paul Taylor The artificial intelligence (AI) deals keep coming. AstraZeneca is the latest drugmaker to open its wallet, agreeing to pay Absci up to $247 million to collaborate on the design of an anti-cancer antibody. |
Sponsored by IQVIA IQVIA’s new technologies are changing clinical trials, reducing the administrative burden on staff and improving insights for sponsors. |
By Helen Floersh Researchers have used unaltered human tracheal cells to create self-assembling multicellular robots capable of healing wounded neurons in a petri dish. |
By Angus Liu As AbbVie and Johnson & Johnson, AstraZeneca and BeiGene are battling it out in the same BTK inhibitor market, Eli Lilly is trailblazing a new path for the blood cancer drug class with an accelerated approval in post BTK/BCL-2 chronic lymphocytic leukemia. |
By Conor Hale The former Fierce Medtech Fierce 15 winner announced it has begun to voluntarily restructure its equity through pre-negotiated terms filed in Delaware bankruptcy court. |
By Nick Paul Taylor The unmet need in non-alcoholic steatohepatitis (NASH) is getting bigger and bigger. Over the decade up to 2032, the number of diagnosed cases in seven major markets is forecast to grow by 4.5 million, creating a bigger pie for the drugmakers that ultimately crack the troublesome indication. |
By Annie Burky,Anastassia Gliadkovskaya,Heather Landi,Paige Minemyer,Dave Muoio,Noah Tong Meet our 2023 Women of Influence. Each of the 10 women profiled this year is playing a major role in driving the industry forward. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| Edison Ballroom, New York City |
|
|
| |
|
